Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA To Evaluate Prescribing In Pregnancy With “Mental Modeling” Of Doctors

Executive Summary

An FDA study to monitor prescribing decisions among care physicians who treat pregnant women could help pave the way for a better understanding of how to communicate drug risks in general

You may also be interested in...



Registries Rising: FDA Looking At TNF Inhibitors; AHRQ Updates Standards

The FDA Amendments Act of 2007 gave the agency many new safety powers and the potential for promotional restrictions and post-marketing fines have understandably received much industry attention. But FDA also appears to be drawing upon its beefed-up authority to increase use of a much older, low-tech safety effort: the patient registry

Registries Rising: FDA Looking At TNF Inhibitors; AHRQ Updates Standards

The FDA Amendments Act of 2007 gave the agency many new safety powers and the potential for promotional restrictions and post-marketing fines have understandably received much industry attention. But FDA also appears to be drawing upon its beefed-up authority to increase use of a much older, low-tech safety effort: the patient registry

FDA Risk Communication Strategy May Include Overhaul Of Labeling Language

As FDA assesses its new risk management powers and overall drug safety strategy, it continues to focus on how to revise what has been its primary communications tool for decades - product labeling

Related Content

UsernamePublicRestriction

Register

PS050144

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel